Old Web
English
Sign In
Acemap
>
authorDetail
>
Noa Popovits-Hadari
Noa Popovits-Hadari
Pathology
Lung cancer
Medicine
Cancer research
Group A
3
Papers
74
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
3rd-line anaplastic lymphoma kinase (ALK) inhibitors (ALKi) in advanced non-small cell lung cancer (aNSCLC): Real-world comparison to non-ALKi therapy.
2020
Journal of Clinical Oncology
Natalie Maimon
Elizabeth Dudnik
Yakir Rottenberg
Noa Popovits-Hadari
Noam Asna
Mira Wollner
Alona Zer
Maya Gottfried
Moshe Mishaeli
Yulia Rovitsky-Gelis
Anastasiya Lobachov
Amir Onn
Damien Urban
Mor Moskovitz
Jair Bar
Show All
Source
Cite
Save
Citations (0)
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors
2018
Journal of Thoracic Oncology
Elizabeth Dudnik
Nir Peled
Hovav Nechushtan
Mira Wollner
Amir Onn
Abed Agbarya
Mor Moskovitz
Shoshana Keren
Noa Popovits-Hadari
Damien Urban
Moshe Mishaeli
Alona Zer
Aaron M. Allen
Natalie Maimon Rabinovich
O. Rotem
Teodor Kuznetsov
Tzippy Shochat
Laila C. Roisman
Jair Bar
Show All
Source
Cite
Save
Citations (74)
Prognostic impact of first treatment choice in EGFR mutant non-small cell lung cancer (mNSCLC) patients (pts) per mutation type; retrospective analysis.
2015
Journal of Clinical Oncology
Jair Bar
Maya Gottfried
Julia Dudnik
Dov Flex
Shoshana P. Keren-Rosenberg
Abed Agbarya
Amir Onn
Mor Moskovitz
Natalie Maimon
Irena Lazarev
Nir Peled
Noa Popovits-Hadari
Haim Biran
Damien Urban
Liv Herscovici
Mira Wollner
Show All
Source
Cite
Save
Citations (0)
1